NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 165 filers reported holding NEKTAR THERAPEUTICS in Q4 2014. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,761,732 | +4569.3% | 2,936,218 | +5347.5% | 0.00% | – |
| Q1 2023 | $37,730 | -62.3% | 53,900 | +73.1% | 0.00% | – |
| Q3 2022 | $100,000 | -79.8% | 31,144 | -15.0% | 0.00% | -100.0% |
| Q4 2021 | $495,000 | -67.5% | 36,643 | -58.7% | 0.00% | -85.7% |
| Q2 2021 | $1,523,000 | -16.5% | 88,751 | +5.0% | 0.01% | -46.2% |
| Q4 2019 | $1,825,000 | -78.0% | 84,520 | -65.8% | 0.01% | -66.7% |
| Q1 2019 | $8,312,000 | +36.2% | 247,434 | +33.3% | 0.04% | -37.1% |
| Q4 2018 | $6,101,000 | +687.2% | 185,608 | +2445.7% | 0.06% | +93.8% |
| Q1 2018 | $775,000 | +80.7% | 7,291 | -66.0% | 0.03% | +68.4% |
| Q2 2017 | $429,000 | -95.8% | 21,444 | -97.4% | 0.02% | -71.6% |
| Q4 2016 | $10,184,000 | -0.9% | 829,982 | +38.7% | 0.07% | -8.2% |
| Q3 2016 | $10,277,000 | +203.2% | 598,207 | +151.2% | 0.07% | +160.7% |
| Q2 2016 | $3,389,000 | -38.0% | 238,180 | -26.5% | 0.03% | -45.1% |
| Q4 2015 | $5,462,000 | +466.6% | 324,124 | +305.6% | 0.05% | +264.3% |
| Q3 2014 | $964,000 | – | 79,904 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |